Denmark Asks Doctors to Move Ozempic Patients to Cheaper Drugs

In Novo Nordisk A/S’s home country of Denmark, authorities now ask doctors to start moving Ozempic patients on to cheaper drugs ahead of stricter subsidies rules coming later this year.

Denmark’s health authority and drug regulator requested on Thursday doctors prepare by reviewing “each individual patient” using Novo’s diabetes medicine Ozempic, to assess whether a patient should switch to “a relevant and cheaper treatment alternative.”

The new rules were announced earlier this month and will take effect in November. They restrict public subsidies for GLP-1 analogues used to treat type 2 diabetes by only reimbursing patients who can’t be ...